PHASE II SBIR FOR PROCESS DEVELOPMENT AND MANUFACTURE OF AN ANTIBODY-BASED THERAPY AGAINST MARBURGVIRUS.
$999,399
| Recipient | BIOFACTURA INC UEI C1ZWQAYK4J58 |
|---|---|
| Award ID | HDTRA120C0033 |
| Award amount | $999,399 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Defense — Defense Threat Reduction Agency |
| NAICS | 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) |
| PSC | AD92 |
| Start date | Jun 15, 2020 |
| End date | Sep 14, 2022 |
| Place of performance | FREDERICK, MD |
| Record updated | Mar 28, 2025 |
View the official award record
More awards won by BIOFACTURA INC
THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS
Department of Health and Human Services · $65,806,222 · Sep 26, 2019
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids